Brought to you by BULLS N’ BEARSMurray WardJuly 8, 2026 — 2:28pmProteomics International Laboratories has secured a vital US patent for its innovative PromarkerEndo blood test, a move that establishes a commercial beachhead into the world’s largest healthcare market and validates a key part of its global strategy.The United States Patent and Trademark Office (USPTO) granted the new patent for the company’s novel diagnostic test for endometriosis. This painful condition affects one in nine women and currently takes an average of seven years to diagnose, often requiring invasive surgery.Proteomics International says its PromarkerEndo blood test could provide early screening for endometriosis, a condition that affects one in nine women.The PromarkerEndo test for endometriosis, now with a US patent in hand, could significantly shorten the diagnostic pathway for a condition with a well-known history of frustrating delays. Proteomics pegs its potential US market at 360,000 annual tests.The patent, titled ‘Endometriosis Biomarkers’, covers the methods of diagnosing the condition using specific protein biomarkers in blood samples.‘This significantly strengthens our position for future partnerships, licensing discussions and regulatory reimbursement advancement.’Proteomics International Laboratories managing director and chief executive officer David MorrisNotably, it provides intellectual property protection in the US until March 2041 and strengthens the company’s hand for future partnerships and licensing discussions. The patent is also likely to smooth the all-important path to regulatory reimbursement, where the government and health insurers set a standard payment rate for the test.Proteomics International Laboratories managing director and chief executive officer David Morris said: “The grant of this patent by USPTO is a major achievement and an important validation of the novelty and commercial potential of PromarkerEndo.”The latest milestone is more than just a single win; it’s another plank in a much broader strategic pivot for the Perth-based company.Under new managing director and chief executive officer, David Morris, Proteomics has drawn a line under its long research phase and is now marching towards what every listed biotech eventually needs, commercial traction.In a fresh strategy presentation, the company outlined a disciplined three-year plan to convert its proteomics science platform into a scalable diagnostics business. For smaller life sciences players, that transition from the lab to the sales ledger can be the toughest hurdle, although Proteomics appears well aware of the challenge.The company has chosen a capital-light route, leaning on distribution partners rather than building expensive in-house sales teams. Management says this model should enable earlier market adoption, lower establishment risk and deliver better capital efficiency.While the new patent shines a light on PromarkerEndo, it is just one of four tests in the company’s portfolio. Leading the charge is PromarkerD, a blood test that predicts diabetes-related chronic kidney disease up to four years before symptoms appear. Proteomics estimates an initial addressable market of 390,000 annual tests in the US alone.Another offering, PromarkerEso, is designed to help rule out throat cancer in patients with chronic reflux, potentially replacing invasive endoscopies with a simple blood test.Rounding out the stable is OxiDx, an oxidative stress testing platform that could find a home in specialist medicine and even the elite athletic and equine markets.The company says it has laid out its roadmap in careful stages. By the first half of fiscal 2027, Proteomics plans to appoint an Australian distributor and launch local controlled market releases for PromarkerEndo. By the second half, it aims to have a US distribution network established and begin reimbursement submissions in both countries.That reimbursement angle could be the real prize. In Australia, a listing on the Medicare Benefits Schedule should materially widen patient access. In the US, success often comes payer by payer, a slower but potentially more lucrative path once momentum builds.With a refreshed board, a new CEO with commercialisation experience, four products on deck and a key US patent now secured, Proteomics looks to be entering a stage where the market may start asking not just what the science can do, but what the future revenue line might look like.Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.auFrom our partners